Anti-(apolipoprotein A-1) IgGs are associated with high levels of oxidized low-density lipoprotein in acute coronary syndrome

Autor: François Mach, Guido Reber, Jean-Michel Dayer, Pierre R. Burkhard, Lionel Fontao, Marc Philip Righini, Nicolas Vuilleumier, Jean-Claude Chevrolet, Natacha Turck, Johan Frostegård, Emmanuel Charbonney, Jean-Charles Sanchez, Noury Mensi, Pascale Roux-Lombard, Richard W. James, Montserrat Alvarez
Rok vydání: 2007
Předmět:
Male
Apolipoprotein A-I/immunology
Apolipoprotein B
Immunoglobulin E
Lipoproteins LDL/blood
Prospective Studies
Biological Markers/blood
Stroke
Acute Coronary Syndrome/blood/immunology
ddc:616
Aged
80 and over
biology
General Medicine
Middle Aged
Pulmonary Embolism/immunology
Lipoproteins
LDL
Acute Disease
lipids (amino acids
peptides
and proteins)
Female
Antibody
Adult
medicine.medical_specialty
Acute coronary syndrome
Stroke/immunology
Adolescent
Enzyme-Linked Immunosorbent Assay
Young Adult
Antiphospholipid syndrome
Internal medicine
medicine
Humans
Acute Coronary Syndrome
Aged
Autoantibodies
Apolipoprotein A-I
business.industry
Enzyme-Linked Immunosorbent Assay/methods
Autoantibody
medicine.disease
Endocrinology
Aged 80 and over
Immunoglobulin G/blood
Immunoglobulin G
Immunology
biology.protein
business
Autoantibodies/blood
Pulmonary Embolism
Biomarkers
Lipoprotein
Zdroj: Clinical Science, Vol. 115, No 1 (2008) pp. 25-33
ISSN: 1470-8736
0143-5221
Popis: ApoA-1 (apolipoprotein A-1) is the main component of HDL (high-density lipoprotein) and stabilizes PON-1 (paraoxonase-1), which prevents lipid peroxidation and oxLDL (oxidized low-density lipoprotein) formation. Autoantibodies against apoA-1 [anti-(apoA-1) IgG] have been found in antiphospholipid syndrome and systemic lupus erythematosous, two diseases with an increased risk of thrombotic events, as well as in ACS (acute coronary syndrome). OxLDL levels are also elevated in these diseases. Whether anti-(apoA-1) IgGs exist in other prothrombotic conditions, such as APE (acute pulmonary embolism) and stroke, has not been studied and their potential association with oxLDL and PON-1 activity is not known. In the present study, we determined prospectively the prevalence of anti-(apoA-1) IgG in patients with ACS (n=127), APE (n=58) and stroke (n=34), and, when present, we tested their association with oxLDL levels. The prevalance of anti-(apoA-1) IgG was 11% in the ACS group, 2% in the control group and 0% in the APE and stroke groups. The ACS group had significantly higher median anti-(apoA-1) IgG titres than the other groups of patients. Patients with ACS positive for anti-(apoA-1) IgG had significantly higher median oxLDL values than those who tested negative (226.5 compared with 47.7 units/l; P
Databáze: OpenAIRE
Externí odkaz: